Celularity Inc., a clinical-stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, today announced that its Lifebank division has released its 100th cord blood stem cell unit for use in an autologous cord blood transplant to treat an eight-year-old patient diagnosed with autism spectrum disorder.
Celularity Announces Release of 100th Cord Blood Stem Cell Unit by its Lifebank Division